Brexit Could Weaken Drug Safety Systems In Both UK And EU, Health Alliance Warns
Executive Summary
Losing access to the EudraVigilance drug safety database after Brexit could lead to delays of up to two months in safety signal detection, and up to five months’ delay in managing new signals, says an alliance of industry, UK National Health Service bodies and medical charities. The alliance also warns that efforts to tackle infectious diseases could be impaired if the UK's role in EU health risk reporting systems is diminished.
You may also be interested in...
Post-Brexit UK Could Lose Access To EU’s Drug Safety Database
One of the many ramifications of the UK’s decision to leave the EU is that it could lose access to the revamped EudraVigilance adverse drug reaction database.
Enhanced EudraVigilance System Goes Live, EMA Updates Info For Users
After months of preparations, the European Medicines Agency’s improved pharmacovigilance database has gone live on schedule.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.